Clinical and Cost-Effectiveness of Omalizumab in Concomitant Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Real-World Exploratory Study. (PubMed, J Asthma Allergy) - Sep 26, 2026 - "While the reference originator is not cost-effective over a 52-week horizon at its baseline price in China, stepwise price reductions through centralized procurement and the emergence of affordable biosimilars provides a highly viable economic pathway. Future optimization requires dynamic value-based pricing and targeting high-burden UAD phenotypes."
HEOR • Journal • Real-world evidence • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis
|
|
Chun Chang; Duo Mou; Jingwen Wang; Lifeng Xie; Mingnuo Zheng; Peng Men; Rongsheng Zhao; Xiaohan Xu
|